<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Posttraumatic stress disorder in children and adolescents: Treatment overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Posttraumatic stress disorder in children and adolescents: Treatment overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Posttraumatic stress disorder in children and adolescents: Treatment overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Strawn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brooks Keeshin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Judith A Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3419724548"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Posttraumatic stress disorder (PTSD) in children and adolescents is a severe, often chronic, and impairing mental disorder. PTSD is seen in some individuals after exposure to traumatic experiences involving actual or threatened injury to themselves or others. Traumatic experiences leading to PTSD can include interpersonal violence, accidents, natural disasters, and injuries.</p><p>PTSD is characterized by intrusive thoughts and reminders of the traumatic experience(s), avoidance of trauma reminders, negative mood and cognitions related to the traumatic experience(s), and physiological hyperarousal that lead to significant social, school, and interpersonal problems [<a href="#rid1">1</a>]. PTSD can occur in toddlers as young as age one to two years [<a href="#rid2">2-4</a>]. The consequences of PTSD include elevated risk for other mental disorders and suicide, substantial impairment in role functioning, reduced social and economic opportunity, and earlier onset of chronic diseases, particularly cardiovascular disease.</p><p>This topic addresses the treatment decisions and subsequent management of PTSD in children and adolescents. Psychosocial interventions for PTSD in children and adolescents are discussed elsewhere as are the epidemiology, pathogenesis, clinical manifestations, and course of PTSD in children and adolescents. Topics related to PTSD in adults are found separately.</p><p>The associated algorithms discuss our treatment choices for PTSD in children and adolescents  (<a class="graphic graphic_algorithm graphicRef141792" href="/z/d/graphic/141792.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef142677" href="/z/d/graphic/142677.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14345.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/500.html" rel="external">"Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14616.html" rel="external">"Acute stress disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14699.html" rel="external">"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, assessment, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H1386910567"><span class="h1">INITIAL TREATMENT</span></p><p class="headingAnchor" id="H2344580616"><span class="h2">Trauma-focused psychotherapy: First line for most</span><span class="headingEndMark"> — </span>Our preferred first-line treatment for most children and adolescents with posttraumatic stress disorder (PTSD) is with trauma-focused psychotherapy (eg, trauma-focused cognitive-behavioral therapy) rather than other psychotherapies or medication management.</p><p>Our preference is based on trials showing efficacy for trauma-focused therapies [<a href="#rid5">5-13</a>], limited efficacy for antidepressants and other medications [<a href="#rid14">14-20</a>], and our clinical experience.</p><p>In contrast to the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the treatment of PTSD symptoms in adults, SSRIs do not appear to be efficacious in the treatment of PTSD in children or adolescents. Randomized trials have found treatment with SSRIs to have similar effects on PTSD symptom reduction [<a href="#rid14">14-16</a>] or prevention [<a href="#rid17">17</a>] as compared with placebo. For example, in a randomized trial of 131 children or adolescents (age 6 to 17 years) with PTSD, improvement of PTSD symptoms (as measured by the University of California, Los Angeles [UCLA] PTSD scale-I) were similar after 10 weeks of therapy with <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">sertraline</a> versus placebo [<a href="#rid14">14</a>]. Similar response to sertraline as compared with placebo in children and adolescents with PTSD has been found in another trial [<a href="#rid15">15</a>].</p><p>Further discussion of trauma-focused therapy for PTSD in children and adolescents, including types of trauma-focused therapy, choosing trauma-focused therapy, administration, and efficacy of trauma-focused therapy, can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy", section on 'Trauma-focused psychotherapy as preferred treatment'</a>.)</p><p class="headingAnchor" id="H48882558"><span class="h2">Pharmacologic management: For severe symptoms</span><span class="headingEndMark"> — </span>We use pharmacologic management as the alternative initial treatment when symptom severity precludes the use of trauma-focused psychotherapy or requires immediate stabilization. In cases where the safety of the individual cannot be maintained at home, we involve the parent/caregiver and consider hospitalization. (See  <a class="medical medical_review" href="/z/d/html/1230.html" rel="external">"Suicidal ideation and behavior in children and adolescents: Evaluation and management"</a>.)</p><p class="headingAnchor" id="H662739327"><span class="h1">ADDRESSING PTSD SYMPTOMS AND COMORBIDITIES</span><span class="headingEndMark"> — </span>We use pharmacologic augmentation when posttraumatic stress disorder (PTSD) symptoms such as sleep disruption/dyssomnia, intrusive recollections, hyperarousal, or reactive behaviors (eg, aggression, outbursts) persist despite trauma-focused cognitive-behavioral therapy (TF-CBT)  (<a class="graphic graphic_algorithm graphicRef142677" href="/z/d/graphic/142677.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H4044147127"><span class="h2">Sleep disruption/dyssomnia</span><span class="headingEndMark"> — </span>For individuals that have persistent sleep disturbance (eg, difficulty falling asleep, nightmares, frequent awakening) that limits the response to psychotherapy or causes psychosocial disruption, we augment trauma-focused therapy with the alpha<sub>1</sub> adrenergic antagonist, <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">prazosin</a>. Medications that centrally modulate noradrenergic tone appear to be efficacious for PTSD-related dyssomnias in youth [<a href="#rid20">20-30</a>]. In our clinical experience, improving the child’s sleep can greatly improve daytime functioning, reduce daytime PTSD symptoms, and increase the child’s ability to engage in evidence-based trauma psychotherapy.</p><p>Due to concern for first-dose hypotension, we begin <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">prazosin</a> at 1 mg given 30 minutes before bedtime. We increase by 1 mg every three to four days for the first two weeks, with a clinical re-evaluation once the patient is at 2 or 3 mg. In children under six or in those with side effects (eg, nausea, dizziness) we start at a 0.5 mg and titrate weekly as more gradual titration minimizes orthostatic side effects. We increase the dose until nightmares and overall quality of sleep have significantly improved, which generally occurs at a dose between 2 and 5 mg, and then monitor PTSD, anxiety and depression symptoms over the course of four to eight weeks prior to making further decision about pharmacotherapy. We monitor blood pressure and pulse (sitting and standing) at baseline and at each follow-up appointment. If morning dizziness or other orthostatic symptoms are present, we administer the medication 30 to 60 minutes earlier in the evening. If symptoms persist, we decrease the dose in 1 mg increments until tolerated.</p><p>In a case series of 34 children with PTSD, treatment with <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">prazosin</a> was associated with improvement in PTSD symptoms (as measured on the UCLA PTSD Reaction Index) including sleep subscale scores, intrusive thoughts, negative cognition and mood, and hyperarousal [<a href="#rid25">25</a>]. Most youth responded to doses of ≤5 mg, with approximately a third of youth, primarily adolescents, requiring more than 5 mg/day [<a href="#rid25">25</a>].</p><p>Furthermore, in adults, <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">prazosin</a> has been found to be efficacious and generally well tolerated at dose ranges of 10 to 15 mg at night in the treatment of PTSD-associated sleep disturbances (trouble falling/staying asleep, nightmares) [<a href="#rid31">31-35</a>].</p><p>For individuals who do not respond to <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">prazosin</a> or are intolerant we use an alpha<sub>2</sub> adrenergic agonist such as <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> or <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> as described in the next section.</p><p class="headingAnchor" id="H4194013188"><span class="h2">Hyperarousal, intrusive recollections, and reactive behaviors</span><span class="headingEndMark"> — </span>TF-CBT improves reactive behaviors in children and adolescents with PTSD that are driven by persistent hyperarousal and intrusive symptoms. Additionally, improvement in sleep can dramatically increase the patient’s ability to cope with daytime trauma symptoms. For children or adolescents with persistent and functionally impairing daytime symptoms of PTSD (eg, hyperarousal, intrusive recollections, or other reactive behaviors [PTSD-related aggression, outbursts]) that are not responsive to TF-CBT and/or sleep interventions, we prefer pharmacologic augmentation with a noradrenergic modulator, such as <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> or <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a>. We do not recommend the use of multiple noradrenergic modulator agents in the same patient.</p><p>In our experience, these medications are well tolerated. The most common side effects include dry mouth and sedation [<a href="#rid20">20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guanfacine</strong> – We typically begin <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> (extended release) at 1 mg each evening and increased by 1 mg each week until effective. Recommended target dose range is 0.08 to 0.12 mg/kg/day.</p><p></p><p class="bulletIndent1">In an uncontrolled trial, 19 children (age 6 to 18 years) with symptoms of PTSD were treated with extended-release <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> 1 to 4 mg each evening (mean dose 1.19 mg/0.03 mg/kg) [<a href="#rid36">36</a>]. At eight weeks, reductions in re-experiencing, avoidant, and hyperarousal as measured by the UCLA PTSD Reaction Index were reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonidine</strong> – We typically start at 0.05 to 0.1 mg at night, increase by 0.05 to 0.1 mg every three nights to a maximum dose of 0.2 to 0.5 mg/day.</p><p></p><p class="headingAnchor" id="H49731990"><span class="h2">Combined modality for co-occurring anxiety and/or depression</span><span class="headingEndMark"> — </span>For children or adolescents with PTSD and co-occurring anxiety or depression that does not improve with TF-CBT, or in cases where the onset of the depression or anxiety clearly predates the trauma, we typically augment TF-CBT with a selective serotonin reuptake inhibitor (SSRI).</p><p>Co-occurring anxiety or depression are commonly seen in individuals with PTSD. Although studies demonstrate that TF-CBT improves depressive symptoms among individual with PTSD receiving TF-CBT [<a href="#rid37">37</a>], not all youth will experience remission of depression or anxiety during trauma treatment, especially youth with persistent, comorbid generalized anxiety disorder.</p><p>Our preference for SSRIs is based on efficacy in depressive and anxiety in children and adolescents [<a href="#rid38">38-41</a>]. Initiation, titration, dose, and side effects of antidepressants in the treatment of depression or anxiety in children/adolescents is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1227.html" rel="external">"Pediatric unipolar depression and pharmacotherapy: Choosing a medication", section on 'Choice of medication for acute treatment'</a> and  <a class="medical medical_review" href="/z/d/html/15928.html" rel="external">"Pharmacotherapy for anxiety disorders in children and adolescents"</a>.)</p><p class="headingAnchor" id="H2468997247"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H3002153237"><span class="h2">Monitoring treatment response</span><span class="headingEndMark"> — </span>We typically monitor children’s responses to treatment through child self-reported ratings such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fintermountainhealthcare.org%2Fckr-ext%2FDcmnt%3Fncid%3D529796906&amp;token=2XW%2FsX5DNoGMVRM%2FwoS%2FYSqwKDsBPnkn0rxPkVaA85ia2g5q7Rtb8GECw%2B0ivuRPv%2FY6bBqQKmLFmne6OvLhGW83uuzNoHjwPbVViFJVNxc%3D&amp;TOPIC_ID=104096" target="_blank">Pediatric Traumatic Stress Screening Tool</a>, that has been widely used in primary care and is an adapted form of the validated UCLA PTSD Reaction Index Brief Screen. A full version of the UCLA PTSD Reaction Index is available and helpful for assessment and monitoring in mental health settings. Other options include the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aacap.org%2FApp_Themes%2FAACAP%2Fdocs%2Fresource_centers%2Fresources%2Fmisc%2Fchild_ptsd_symptom_scale.pdf&amp;token=s2GT9b2%2FNT2ze8kgzp4AxaQzaalrkEEp7S%2BDIDComByY5Nf%2Fk%2BTKFtB4ZLTYaMIJPLxyTWEbwJUKAVHVWBmdYQm%2Ba0dGp7tF1OCqtyXrGYDqqrJkOQ1nUyzQW7eGLn7G&amp;TOPIC_ID=104096" target="_blank">Child PTSD Symptom Scale</a> or the Child and Adolescent Trauma Screen-2 (for children age 7 to 17 years). For younger children (ie, &lt;7 years old), we use the parent-reported instrument <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.michaelscheeringa.com%2Fuploads%2F1%2F2%2F0%2F2%2F120202234%2Fycpc_2014_5_23.pdf&amp;token=6Ysxh1RSuP5pbLUOfjafG5ByZ%2Bpww3dMMcT4HVCDLiGiBxS9qEWioodHckJ3JO3DaWWHvY5iIexNsL1hTkkVvTjVbE1ef4Be6aothOd30XI%3D&amp;TOPIC_ID=104096" target="_blank">Young Child PTSD Checklist</a>. We administer these at pretreatment and after each treatment phase. Clinically significant improvement (eg, from the very severe to moderate range; or from the severe to mild range using the norms established on the respective instrument; or a decrease in score of &gt;40 percent) defines response.</p><p class="headingAnchor" id="H2668811722"><span class="h2">Robust response</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ongoing/maintenance psychotherapy</strong> – For children or adolescents with robust response to treatment (either psychosocial intervention or combination treatment), we encourage ongoing implementation of the skills learned during therapy. This is particularly true regarding response to reminders of trauma which can prompt symptom recurrence. We encourage booster psychotherapy sessions if symptoms recur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of pharmacotherapy</strong> – We review the risk and benefit of ongoing treatment and, working with the patient and parent/caregiver, weigh this against the risk and benefit of tapering medication. For those that we agree to taper off of medications (eg, favorable response, no recurrence of symptoms, no prior recurrence of symptoms with taper), we taper most medications slowly and generally over a period three to four months during or towards the end of the trauma therapy [<a href="#rid42">42</a>]. <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">Prazosin</a> can generally be stopped without a taper, although some families may prefer to more slowly wean off the medication. In contrast, when pharmacologic management of comorbid anxiety or depression has been effective, we continue it for a minimum of nine months to one year [<a href="#rid43">43</a>].</p><p></p><p class="headingAnchor" id="H1202360189"><span class="h2">Limited or minimal response</span></p><p class="headingAnchor" id="H3233639158"><span class="h3">Confirm diagnosis, address stressors, optimize psychotherapy</span><span class="headingEndMark"> — </span>In individuals with limited or no response to psychotherapy, our next steps are to review the diagnosis, address factors that may be limiting response to treatment, and optimize psychotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Review diagnosis and address co-occurring disorders </strong>– Disorders such as depression, generalized anxiety disorder, substance use disorders, and obsessive-compulsive disorder often co-occur with chronic posttraumatic stress disorder (PTSD). We do not consider PTSD to be nonresponsive to treatment until the after the comorbid disorder is adequately treated. (See <a class="local">'Combined modality for co-occurring anxiety and/or depression'</a> above and  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy", section on 'Children with co-occurring conditions'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Complex PTSD </strong>–<strong> </strong>Poor or delayed response to trauma-focused psychotherapy may suggest the presence of complex PTSD. In these cases, we typically provide somewhat lengthier treatment, with a longer initial stabilization phase.</p><p></p><p class="bulletIndent2">Complex PTSD is not included in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) but is described in the International Classification of Diseases, 11<sup>th</sup> Revision (ICD-11). Complex PTSD differs from noncomplex PTSD in the subject’s history of chronic trauma and, in addition to core PTSD features, the presence of prominent features of affective dysregulation, negative self-concept and interpersonal disturbances [<a href="#rid44">44-49</a>]. Most treatments with efficacy for child PTSD have been successfully applied to the subgroup with complex trauma [<a href="#rid50">50</a>]. Other treatments have been developed specifically for these youth [<a href="#rid51">51-53</a>]. Further discussion of treatment of teens with complex PTSD can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy", section on 'Teens with complex PTSD'</a> and  <a class="medical medical_review" href="/z/d/html/14699.html" rel="external">"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Address stressors such as ongoing trauma or other environmental factors </strong>– Symptoms of PTSD may persist despite appropriate treatment when trauma recurs during the treatment. Adaptive trauma responses such as increased vigilance, increased focus on safety, differentiating between real danger and trauma reminders, and helping nonoffending parents/caregivers to collaborate with children to develop additional strategies for enhancing safety may be effective in reducing PTSD and other comorbid symptoms [<a href="#rid8">8,54</a>].</p><p></p><p class="bulletIndent1">Many features of a traumatized child’s daily life (eg, family, health, educational, community, faith, legal, and child welfare) are likely to influence treatment response [<a href="#rid55">55</a>]. Examples include changes in foster family placement or the arrest/incarceration or illness/death of a family member. Secondary adversities, losses and other significant stressors emphasize the critical importance of working collaboratively with parents/caregivers to be proactively aware of potential changes that may occur in the child’s life and address perceived or real threats to the child’s safety that may occur as a result of these changes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimize psychotherapy</strong> – We pay particular attention to treatment fidelity and review trauma reminders.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment fidelity</strong> – We recommend appropriate training and supervision for all treatment providers utilizing trauma-focused psychotherapy. Treatment nonresponse may occur when the core treatment components are provided incorrectly or not at all.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trauma reminders</strong> – We review trauma reminders or triggers, develop different coping strategies for these triggers, and help the child to master the coping strategies identified (eg, during in-session practice). (See  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy", section on 'Administering TF-CBT'</a>.)</p><p></p><p class="headingAnchor" id="H3601503108"><span class="h3">Changes to psychotherapy</span><span class="headingEndMark"> — </span>After addressing the above factors, if limited or no response persists, we make changes to the psychotherapy. This includes tailoring the psychotherapy to address the child’s specific symptoms and then, if needed, changing to another trauma-focused therapy. (See  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy"</a>.)</p><p>The associated algorithm discusses our selection of trauma-focused psychotherapy for the treatment of PTSD in children and adolescents  (<a class="graphic graphic_algorithm graphicRef142677" href="/z/d/graphic/142677.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tailoring the psychotherapy </strong>–<strong> </strong>We tailor the psychotherapy to address the child’s specific PTSD symptoms, for example:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We focus the therapy on parenting skills and behavioral regulation skills for hyperarousal symptoms (eg, angry outbursts, irritability, and sleep disturbance).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We review the trauma narrative and cognitive processing of maladaptive cognitions, and emotional expressions for ongoing symptoms of re-experiencing, avoidance, fear, or anxiety [<a href="#rid10">10,56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Switching to another trauma-focused psychotherapy</strong> – If, despite the above interventions, response to trauma-focused therapy is still minimal to none, we switch to another trauma-focused psychotherapy with empirical evidence of effect. As an example, a child who has not responded to trauma-focused group CBT may benefit from trauma-focused individual CBT [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy", section on 'Individual trauma-focused psychotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/89790.html" rel="external">"Posttraumatic stress disorder in children and adolescents: Trauma-focused psychotherapy", section on 'Trauma-focused group treatment'</a>.)</p><p></p><p class="headingAnchor" id="H1914273075"><span class="h3">Medication options</span><span class="headingEndMark"> — </span>Despite some of these medications being used as second-line agents for PTSD with comorbid disorders, we do not use the following medications in the treatment of PTSD in children or adolescents until all of the interventions discussed above have been ineffective. (See <a class="local">'Initial treatment'</a> above and <a class="local">'Addressing PTSD symptoms and comorbidities'</a> above and <a class="local">'Limited or minimal response'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidepressants, beta blockers, antiseizure medications, glutamatergic modulators </strong>– Limited evidence supports the use of serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, beta-blockers, D-Cycloserine, or glutamate modulators in the treatment of PTSD in children or adolescents [<a href="#rid16">16,58-63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-generation antipsychotic medications</strong> – We suggest against the use of second-generation antipsychotics in the treatment of PTSD in children and adolescents. Limited data (uncontrolled trials and case series) have reported mixed results on the use of second-generation antipsychotic medications in youth with PTSD symptoms, as well as high rates of side effects such as weight gain, insulin resistance, dyslipidemia (eg, hypercholesterolemia, hypertriglyceridemia), and extrapyramidal symptoms limit their use [<a href="#rid64">64-66</a>]. Children exposed to childhood trauma are at risk for chronic health problems such as childhood obesity independent of medication use [<a href="#rid67">67</a>], and thus at additional risk with second-generation antipsychotic use. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a>.)</p><p></p><p class="headingAnchor" id="H3717835260"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113176.html" rel="external">"Society guideline links: Anxiety and trauma-related disorders in children"</a>.)</p><p class="headingAnchor" id="H2792846851"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>– Posttraumatic stress disorder (PTSD) in children and adolescents is a severe, often chronic, mental disorder that may lead to significant school, social and interpersonal problems. Symptoms include intrusive thoughts and reminders of the traumatic experience(s), avoidance of trauma reminders, negative mood and cognitions related to the traumatic experience(s), and physiological hyperarousal. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trauma-focused psychotherapy</strong> – For most children or adolescents with PTSD, we suggest trauma-focused psychotherapy rather than other forms of psychotherapy or medication management alone as initial treatment  (<a class="graphic graphic_algorithm graphicRef141792" href="/z/d/graphic/141792.html" rel="external">algorithm 1</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Trauma-focused psychotherapy: First line for most'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic management for severe symptoms</strong> – For children or adolescents whose symptom severity precludes treatment with trauma-focused psychotherapy, or in those requiring immediate stabilization, we use pharmacologic management as an alternative initial treatment  (<a class="graphic graphic_algorithm graphicRef142677" href="/z/d/graphic/142677.html" rel="external">algorithm 2</a>). (See <a class="local">'Pharmacologic management: For severe symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addressing PTSD symptoms and comorbidities </strong>–<strong> </strong>We use pharmacologic augmentation when PTSD symptoms such as sleep disruption/dyssomnia, intrusive recollections, hyperarousal, or reactive behaviors (eg, aggression, outbursts) persist despite trauma-focused cognitive-behavioral therapy (TF-CBT). (See <a class="local">'Addressing PTSD symptoms and comorbidities'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sleep disruption/dyssomnia </strong>– For children or adolescents with persistent dyssomnia that limits response to trauma-focused therapy, we suggest augmentation with <a class="drug drug_pediatric" data-topicid="12722" href="/z/d/drug information/12722.html" rel="external">prazosin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Sleep disruption/dyssomnia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperarousal, intrusive recollection, reactive behaviors</strong> – For children or adolescents with persistent hyperarousal, intrusive recollections, or reactive behaviors (eg, aggression, outbursts) despite treatment with trauma-focused psychotherapy, we suggest augmentation with an anti-adrenergic agent such as <a class="drug drug_pediatric" data-topicid="13171" href="/z/d/drug information/13171.html" rel="external">clonidine</a> or <a class="drug drug_pediatric" data-topicid="15555" href="/z/d/drug information/15555.html" rel="external">guanfacine</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Hyperarousal, intrusive recollections, and reactive behaviors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Combined modality for co-occurring anxiety or depression </strong>– For children or adolescents with PTSD and co-occurring anxiety or depression that does not improve with TF-CBT, or in cases where the onset of the depression or anxiety clearly predates the trauma, we typically augment TF-CBT with a selective serotonin reuptake inhibitor (SSRI). (See <a class="local">'Combined modality for co-occurring anxiety and/or depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent management</strong> – For limited or minimal response to initial management with psychotherapy with or without pharmacotherapy, we confirm the diagnosis, address stressors, and optimize the psychotherapy, including tailoring the psychotherapy to address specific symptoms. If symptoms persist despite these measures, we typically switch to another trauma-focused psychotherapy. (See <a class="local">'Confirm diagnosis, address stressors, optimize psychotherapy'</a> above.)</p><p></p><p class="bulletIndent1">Limited data support the use of non-SSRI antidepressants, <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a>, mood stabilizers, and glutamatergic modulators in the treatment of PTSD in children and adolescents. We do not use these or second-generation antipsychotics as part of the treatment of PTSD in children and adolescents. (See <a class="local">'Medication options'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li><a class="nounderline abstract_t">Meiser-Stedman R, Smith P, Glucksman E, et al. The posttraumatic stress disorder diagnosis in preschool- and elementary school-age children exposed to motor vehicle accidents. Am J Psychiatry 2008; 165:1326.</a></li><li><a class="nounderline abstract_t">Graf A, Irblich D, Landolt MA. [Posttraumatic stress disorder in infants and toddlers]. Prax Kinderpsychol Kinderpsychiatr 2008; 57:247.</a></li><li class="breakAll">Trauma. Zero To Three. http://zerotothree.org/issue-areas/trauma/ (Accessed on September 20, 2021).</li><li class="breakAll">Deblinger E, Mannarino AP, Cohen JA. Theory, treatment development, and research. In: Child Sexual Abuse: A Primer For Treating Children, Adolescents, and Their Non-Offending Parents, 2nd ed, Oxford Press, New York 2015. p.19.</li><li><a class="nounderline abstract_t">Cohen JA, Mannarino AP, Knudsen K. Treating sexually abused children: 1 year follow-up of a randomized controlled trial. Child Abuse Negl 2005; 29:135.</a></li><li><a class="nounderline abstract_t">Cohen JA, Deblinger E, Mannarino AP, Steer RA. A multisite, randomized controlled trial for children with sexual abuse-related PTSD symptoms. J Am Acad Child Adolesc Psychiatry 2004; 43:393.</a></li><li><a class="nounderline abstract_t">Cohen JA, Mannarino AP, Iyengar S. Community treatment of posttraumatic stress disorder for children exposed to intimate partner violence: a randomized controlled trial. Arch Pediatr Adolesc Med 2011; 165:16.</a></li><li><a class="nounderline abstract_t">Cohen JA, Mannarino AP. A treatment outcome study for sexually abused preschool children: initial findings. J Am Acad Child Adolesc Psychiatry 1996; 35:42.</a></li><li><a class="nounderline abstract_t">Deblinger E, Steer RA, Lippmann J. Two-year follow-up study of cognitive behavioral therapy for sexually abused children suffering post-traumatic stress symptoms. Child Abuse Negl 1999; 23:1371.</a></li><li><a class="nounderline abstract_t">Gillies D, Taylor F, Gray C, et al. Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents. Cochrane Database Syst Rev 2012; 12:CD006726.</a></li><li><a class="nounderline abstract_t">O'Callaghan P, McMullen J, Shannon C, et al. A randomized controlled trial of trauma-focused cognitive behavioral therapy for sexually exploited, war-affected Congolese girls. J Am Acad Child Adolesc Psychiatry 2013; 52:359.</a></li><li><a class="nounderline abstract_t">McMullen J, O'Callaghan P, Shannon C, et al. Group trauma-focused cognitive-behavioural therapy with former child soldiers and other war-affected boys in the DR Congo: a randomised controlled trial. J Child Psychol Psychiatry 2013; 54:1231.</a></li><li><a class="nounderline abstract_t">Robb AS, Cueva JE, Sporn J, et al. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol 2010; 20:463.</a></li><li><a class="nounderline abstract_t">Cohen JA, Mannarino AP, Perel JM, Staron V. A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms. J Am Acad Child Adolesc Psychiatry 2007; 46:811.</a></li><li><a class="nounderline abstract_t">Robert R, Tcheung WJ, Rosenberg L, et al. Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study. Burns 2008; 34:919.</a></li><li><a class="nounderline abstract_t">Stoddard FJ Jr, Luthra R, Sorrentino EA, et al. A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children. J Child Adolesc Psychopharmacol 2011; 21:469.</a></li><li><a class="nounderline abstract_t">Keeshin B, Forkey HC, Fouras G, et al. Children Exposed to Maltreatment: Assessment and the Role of Psychotropic Medication. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Cohen JA, Bukstein O, Walter H, et al. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry 2010; 49:414.</a></li><li><a class="nounderline abstract_t">Keeshin BR, Strawn JR. Treatment of Children and Adolescents with Posttraumatic Stress Disorder (PTSD): A Review of Current Evidence. Child Adolesc Psychopharmacol News 2010; 17:5.</a></li><li><a class="nounderline abstract_t">Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158:1227.</a></li><li><a class="nounderline abstract_t">Strawn JR, Geracioti TD Jr. Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder. Depress Anxiety 2008; 25:260.</a></li><li><a class="nounderline abstract_t">Pervanidou P, Kolaitis G, Charitaki S, et al. The natural history of neuroendocrine changes in pediatric posttraumatic stress disorder (PTSD) after motor vehicle accidents: progressive divergence of noradrenaline and cortisol concentrations over time. Biol Psychiatry 2007; 62:1095.</a></li><li><a class="nounderline abstract_t">Keeshin BR, Strawn JR, Out D, et al. Elevated salivary alpha amylase in adolescent sexual abuse survivors with posttraumatic stress disorder symptoms. J Child Adolesc Psychopharmacol 2015; 25:344.</a></li><li><a class="nounderline abstract_t">Keeshin BR, Ding Q, Presson AP, et al. Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review. Neurol Ther 2017; 6:247.</a></li><li><a class="nounderline abstract_t">Strawn JR, Keeshin BR. Successful treatment of posttraumatic stress disorder with prazosin in a young child. Ann Pharmacother 2011; 45:1590.</a></li><li><a class="nounderline abstract_t">Strawn JR, Delbello MP, Geracioti TD. Prazosin treatment of an adolescent with posttraumatic stress disorder. J Child Adolesc Psychopharmacol 2009; 19:599.</a></li><li><a class="nounderline abstract_t">Brkanac Z, Pastor JF, Storck M. Prazosin in PTSD. J Am Acad Child Adolesc Psychiatry 2003; 42:384.</a></li><li><a class="nounderline abstract_t">Fraleigh LA, Hendratta VD, Ford JD, Connor DF. Prazosin for the treatment of posttraumatic stress disorder-related nightmares in an adolescent male. J Child Adolesc Psychopharmacol 2009; 19:475.</a></li><li><a class="nounderline abstract_t">Hudson N, Burghart S, Reynoldson J, Grauer D. Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents. Ment Health Clin 2021; 11:45.</a></li><li><a class="nounderline abstract_t">Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63:629.</a></li><li><a class="nounderline abstract_t">Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 2007; 61:928.</a></li><li><a class="nounderline abstract_t">Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160:371.</a></li><li><a class="nounderline abstract_t">Raskind MA, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry 2013; 170:1003.</a></li><li><a class="nounderline abstract_t">Singh B, Hughes AJ, Mehta G, et al. Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis. Prim Care Companion CNS Disord 2016; 18.</a></li><li><a class="nounderline abstract_t">Connor DF, Grasso DJ, Slivinsky MD, et al. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. J Child Adolesc Psychopharmacol 2013; 23:244.</a></li><li><a class="nounderline abstract_t">Morina N, Koerssen R, Pollet TV. Interventions for children and adolescents with posttraumatic stress disorder: A meta-analysis of comparative outcome studies. Clin Psychol Rev 2016; 47:41.</a></li><li><a class="nounderline abstract_t">Hetrick SE, McKenzie JE, Bailey AP, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Cochrane Database Syst Rev 2021; 5:CD013674.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Hur K, Brown CH, et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69:572.</a></li><li><a class="nounderline abstract_t">Uthman OA, Abdulmalik J. Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis. Curr Med Res Opin 2010; 26:53.</a></li><li><a class="nounderline abstract_t">Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158:2008.</a></li><li><a class="nounderline abstract_t">Strawn JR, Mills JA, Poweleit EA, et al. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2022.</a></li><li><a class="nounderline abstract_t">Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? Curr Probl Pediatr Adolesc Health Care 2018; 48:31.</a></li><li><a class="nounderline abstract_t">Terr LC. Childhood traumas: an outline and overview. Am J Psychiatry 1991; 148:10.</a></li><li class="breakAll">Herman JL. Sequelae of prolonged and repeated trauma: evidence for a complex posttraumatic syndrome (DESNOS). In: Posttraumatic Stress Disorder: DSM-IV and Beyond, Davidson, JRT, Foa, EB (Eds), American Psychiatric Press, Washington, DC 1993. p.213.</li><li class="breakAll">National Child Traumatic Stress Network. Understanding child traumatic stress. http://nctsn.org/resources/audiences/parents-caregivers/understanding-child-traumatic-stress (Accessed on October 27, 2015).</li><li><a class="nounderline abstract_t">Cook A, Spinazzola J, Ford J, et al. Complex trauma in children and adolescents. Psychiatr Ann 2005; 35:390.</a></li><li class="breakAll">NCTSN Core Curriculum on Childhood Trauma Task Force. The 12 core concepts: Concepts for understanding traumatic stress responses in children and families. Core Curriculum on Child Trauma. http://nctsn.org/resources/audiences/parents-caregivers/what-is-cts/12-core-concepts (Accessed on October 27, 2015).</li><li><a class="nounderline abstract_t">Cloitre M, Garvert DW, Brewin CR, et al. Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis. Eur J Psychotraumatol 2013; 4.</a></li><li class="breakAll">Trauma-focused CBT for children and adolescents: Treatment applications, Cohen JA, Mannarino AP, Deblinger E (Eds), Guilford Press, New York 2012.</li><li><a class="nounderline abstract_t">Ford JD, Steinberg KL, Hawke J, et al. Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency. J Clin Child Adolesc Psychol 2012; 41:27.</a></li><li><a class="nounderline abstract_t">Cohen JA, Mannarino AP, Kliethermes M, Murray LA. Trauma-focused CBT for youth with complex trauma. Child Abuse Negl 2012; 36:528.</a></li><li class="breakAll">Blaustein ME, Kinniburgh KM. Treating traumatic stress in children and adolescents: how to foster resilience through attachment, self-regulation and competence, Guilford Press, New York 2010.</li><li><a class="nounderline abstract_t">Cohen JA, Mannarino AP, Murray LK. Trauma-focused CBT for youth who experience ongoing traumas. Child Abuse Negl 2011; 35:637.</a></li><li class="breakAll">Saxe GN, Ellis BH, Kaplow JB. Collaborative treatment of traumatized children and teens: The trauma systems therapy approach, Guilford Press, New York 2007.</li><li><a class="nounderline abstract_t">Mundorf ES, Paivio SC. Narrative quality and disturbance pre- and post-emotion-focused therapy for child abuse trauma. J Trauma Stress 2011; 24:643.</a></li><li><a class="nounderline abstract_t">Jaycox LH, Cohen JA, Mannarino AP, et al. Children's mental health care following Hurricane Katrina: a field trial of trauma-focused psychotherapies. J Trauma Stress 2010; 23:223.</a></li><li><a class="nounderline abstract_t">Nugent NR, Christopher NC, Crow JP, et al. The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study. J Trauma Stress 2010; 23:282.</a></li><li><a class="nounderline abstract_t">Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. Am J Dis Child 1988; 142:1244.</a></li><li><a class="nounderline abstract_t">Looff D, Grimley P, Kuller F, et al. Carbamazepine for PTSD. J Am Acad Child Adolesc Psychiatry 1995; 34:703.</a></li><li><a class="nounderline abstract_t">Steiner H, Saxena KS, Carrion V, et al. Divalproex sodium for the treatment of PTSD and conduct disordered youth: a pilot randomized controlled clinical trial. Child Psychiatry Hum Dev 2007; 38:183.</a></li><li><a class="nounderline abstract_t">Scheeringa MS, Weems CF. Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol 2014; 24:69.</a></li><li><a class="nounderline abstract_t">Gupta S, Austin R, Cali LA, Bhatara V. Nightmares treated with cyproheptadine. J Am Acad Child Adolesc Psychiatry 1998; 37:570.</a></li><li><a class="nounderline abstract_t">Stathis S, Martin G, McKenna JG. A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center. J Clin Psychopharmacol 2005; 25:539.</a></li><li><a class="nounderline abstract_t">Horrigan J, Barnhill L. Risperidone and PTSD in boys. J Neuropsychiatry Clin Neurosci 1999; 11:126.</a></li><li><a class="nounderline abstract_t">Keeshin BR, Strawn JR. Risperidone treatment of an adolescent with severe posttraumatic stress disorder. Ann Pharmacother 2009; 43:1374.</a></li><li><a class="nounderline abstract_t">Keeshin BR, Luebbe AM, Strawn JR, et al. Sexual abuse is associated with obese children and adolescents admitted for psychiatric hospitalization. J Pediatr 2013; 163:154.</a></li></ol></div><div id="topicVersionRevision">Topic 104096 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676592" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The posttraumatic stress disorder diagnosis in preschool- and elementary school-age children exposed to motor vehicle accidents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575054" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : [Posttraumatic stress disorder in infants and toddlers].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575054" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : [Posttraumatic stress disorder in infants and toddlers].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18575054" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [Posttraumatic stress disorder in infants and toddlers].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734179" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treating sexually abused children: 1 year follow-up of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187799" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A multisite, randomized controlled trial for children with sexual abuse-related PTSD symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199975" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Community treatment of posttraumatic stress disorder for children exposed to intimate partner violence: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8567611" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A treatment outcome study for sexually abused preschool children: initial findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10626618" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Two-year follow-up study of cognitive behavioral therapy for sexually abused children suffering post-traumatic stress symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235632" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Psychological therapies for the treatment of post-traumatic stress disorder in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23582867" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A randomized controlled trial of trauma-focused cognitive behavioral therapy for sexually exploited, war-affected Congolese girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23738530" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Group trauma-focused cognitive-behavioural therapy with former child soldiers and other war-affected boys in the DR Congo: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186964" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17581445" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A pilot randomized controlled trial of combined trauma-focused CBT and sertraline for childhood PTSD symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18675519" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Treating thermally injured children suffering symptoms of acute stress with imipramine and fluoxetine: a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22040192" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A randomized controlled trial of sertraline to prevent posttraumatic stress disorder in burned children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31964760" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Children Exposed to Maltreatment: Assessment and the Role of Psychotropic Medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410735" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Treatment of Children and Adolescents with Posttraumatic Stress Disorder (PTSD): A Review of Current Evidence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11481155" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CSF norepinephrine concentrations in posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17354267" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Noradrenergic dysfunction and the psychopharmacology of posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17624319" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The natural history of neuroendocrine changes in pediatric posttraumatic stress disorder (PTSD) after motor vehicle accidents: progressive divergence of noradrenaline and cortisol concentrations over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25803321" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Elevated salivary alpha amylase in adolescent sexual abuse survivors with posttraumatic stress disorder symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28755207" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22116993" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Successful treatment of posttraumatic stress disorder with prazosin in a young child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877989" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prazosin treatment of an adolescent with posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649625" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prazosin in PTSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19702502" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prazosin for the treatment of posttraumatic stress disorder-related nightmares in an adolescent male.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33850681" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of low dose prazosin for PTSD-associated nightmares in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17868655" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17069768" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12562588" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846759" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27828694" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of Prazosin in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23683139" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27340855" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Interventions for children and adolescents with posttraumatic stress disorder: A meta-analysis of comparative outcome studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34029378" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : New generation antidepressants for depression in children and adolescents: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22393205" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19905879" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11729017" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adverse effects of antidepressant medications and their management in children and adolescents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29337001" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824611" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Childhood traumas: an outline and overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824611" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Childhood traumas: an outline and overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824611" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Childhood traumas: an outline and overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Complex trauma in children and adolescents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Complex trauma in children and adolescents</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687563" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687563" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evidence for proposed ICD-11 PTSD and complex PTSD: a latent profile analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22233243" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Randomized trial comparison of emotion regulation and relational psychotherapies for PTSD with girls involved in delinquency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749612" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Trauma-focused CBT for youth with complex trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22749612" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Trauma-focused CBT for youth with complex trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855140" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Trauma-focused CBT for youth who experience ongoing traumas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21855140" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Trauma-focused CBT for youth who experience ongoing traumas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22144230" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Narrative quality and disturbance pre- and post-emotion-focused therapy for child abuse trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20419730" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Children's mental health care following Hurricane Katrina: a field trial of trauma-focused psychotherapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20419738" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The efficacy of early propranolol administration at reducing PTSD symptoms in pediatric injury patients: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3177336" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608041" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Carbamazepine for PTSD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17570057" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Divalproex sodium for the treatment of PTSD and conduct disordered youth: a pilot randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24506079" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9628074" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Nightmares treated with cyproheptadine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282834" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A preliminary case series on the use of quetiapine for posttraumatic stress disorder in juveniles within a youth detention center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risperidone and PTSD in boys</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19584378" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risperidone treatment of an adolescent with severe posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23414663" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sexual abuse is associated with obese children and adolescents admitted for psychiatric hospitalization.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
